First Half of 2016 Shows Strength in M&A

by | Aug 11, 2016 7:53 pm | Biotechnology, eHealth, Long-Term Care, Pharmaceuticals, Private Equity | 0 comments

Ever since the rally in health care mergers and acquisitions began in 2014, we’ve been waiting for the inevitable slam-on-the-brakes quarter. That rally was sparked by the advent of newly insured families and individuals entering the healthcare market, beginning on January 1, 2014. Thanks to the Affordable Care Act, passed in 2010, health care M&A topped 1,000 transactions that year and has never looked back. Isn’t it about time for the party to end? Not according to our data for the first six months of 2016, compared with the same period in 2014 and 2015. (But if you read our monthly M&A roundup on page 18, you may have second thoughts.) In the first half of 2016, deal volume... Read More »

Takeda’s triple transactions

by | Jul 7, 2016 7:35 pm | Biotechnology, Pharmaceuticals | 0 comments

Takeda Pharmaceutical Company Ltd. (OTCQB: TKPYY) has been busy bolstering its role as a global leader in gastroenterology. On June 8, 2016, Takeda dished out $15 million for Theravance Biopharma’s (NASDAQ: TBPH) license to TD-8954, a selective 5-HT4 receptor agonist being investigated for potential use in gastrointestinal motility disorders, including enteral feeding intolerance. Less than a month later, Takeda bought the rights to develop ATC-1906  from Altos Therapeutics for an undisclosed amount. ATC-1906 is currently in Phase 1 studies for the treatment of gastroparesis and its symptoms. Then, just four days later, on July 5 2016, Takeda paid approximately $28 million to TiGenix N.V.... Read More »